QUADRA is being conducted to find out if nirapirib, an investigational drug called a PARP inhibitor, can help delay the worsening of ovarian, peritoneal, or fallopian tube cancer among patients who have had 3 or 4 previous rounds of chemotherapy.
Is QUADRA right for you? To qualify to participate in the study, you should:
Be at least 18 years old
- Have histologically diagnosed recurrent high-grade serous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Have completed 3 or 4 previous chemotherapy regimens
- Have adequate bone marrow, kidney, and liver function
There are other eligibility criteria that your doctor will discuss with you to see if you qualify for the trial.
What to Expect
About 400 people will participate in this clinical research trial. All participants will receive the study medication (the PARP inhibitor, niraparib).
Participants will take up to three pills once a day.
Throughout the trial, your doctor will continue to monitor your health.
Treatment will continue until the disease progresses or the participant chooses to discontinue.
For more information on the QUADRA clinical research trial, please contact a research site near you.